Synthesis and biological evaluation of novel Sarsasapogenin (cas 126-19-2) derivatives as potential anti-tumor agents

Add time:09/27/2019    Source:sciencedirect.com

Based on the fact that timosaponin A-III (TA-III) exhibits potent cytotoxic effects and has been considered as a potential anti-tumor agent, a range of novel Sarsasapogenin (cas 126-19-2) derivatives 1, 2a–2g, 3, 4, 5, 6a–6g have been synthesized by a simple and facile synthetic route. The in vitro cytotoxic activity of these synthetic compounds has been evaluated against ten human cancer cell lines. The pharmacological results showed that most of the sarsasapogenin derivatives displayed excellent selective cytotoxicity toward the cancer cell lines. An amino group at C-3 or C-26 position of the sapogenin had a profound influence on the cytotoxic activity. In particular, compound 6c exhibited significantly inhibitory activity against A375-S2 (IC50 = 0.56 μM) and HT1080 (IC50 = 0.72 μM) cells. However, introducing a bromo or morpholinyl substituent at the C-3 and C-26 position of the sapogenin generally rendered it inactive against the human cancer cell lines. This research provides a theoretical reference for the exploration of new anti-tumor drugs.

We also recommend Trading Suppliers and Manufacturers of Sarsasapogenin (cas 126-19-2). Pls Click Website Link as below: cas 126-19-2 suppliers

Prev:Quantitative determination of Sarsasapogenin (cas 126-19-2) in rat plasma using liquid chromatography-tandem mass spectrometry
Next:Timosaponin AIII and its metabolite Sarsasapogenin (cas 126-19-2) ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balance)